ALA presents at the 17th Annual Bioshares Biotech Summit
Arovella’s CEO and MD, Dr Michael Baker, will present data describing the key benefits of Arovella’s proprietary iNKT cell therapy platform as truly “off-the-shelf” with the potential for improved efficacy across a range of oncology indications. Highlights from the presentation include:
The “off-the-shelf” capabilities of Arovella’s CAR-iNKT platform
Potential benefits of CAR-iNKT cells over CAR-T in treating cancers
Key advantages of Arovella’s proprietary manufacturing process
The history of iNKT cells as a novel cell type and CAR-iNKT cells as a new treatment opportunity
The potential of ALA-101 in combination with Imugene’s onCARlytics platform to treat solid tumours
The possibility of Arovella’s proprietary iNKT cell platform with novel CARs to target solid tumours
